Infections are a major cause of morbidity and mortality in patients undergoing high-dose therapy and subsequent autologous or allogeneic haemopoietic stem cell transplantation, despite the change from topical to systemic anti-infection prophylaxis and the introduction of growth factors and new antimicrobial drugs. We report our single centre experience with data from 409 patients treated at our unit from its opening in 1990 until May 1997. Three hundred and seventy-eight patients were transplanted for the first time, 12 patients were retransplanted or boosted and 19 patients were readmitted for miscellaneous reasons. 245 patients were allografted and 157 autografted. Antimicrobial prophylaxis was mainly quinolones, fluconazole plus amphotericin-B orally, aciclovir, and TMP/SMX or pentamidine. Three hundred and nineteen (78%) developed fever of significantly longer duration in the allogeneic setting with anti-CMV seropositivity. The most frequent infection was fever of unknown origin (50.6%), followed by septicaemia (12.5%) and pneumonia (11.0%). Pathogens isolated in 24.6% of the infections were mostly grampositive bacteria (57.9%), followed by non-fermenting rods (11.2%), Aspergillus spp. and Candida spp. Systemic infection with these pathogens is associated with a poor prognosis. Antimycotic prophylaxis and the therapy must be improved.
transplantation; high-dose therapy; allogeneic; infection; bacteria Infections are a major cause of morbidity and death in patients undergoing high-dose therapy followed by allogeneic or autologous bone marrow or blood stem cell transplantation. [1] [2] [3] During high-dose therapy-induced neutropenia, bacteria and fungi are the predominant pathogens. Fever in neutropenic patients requires immediate broadspectrum antibiotic therapy. 4 Patients undergoing myeloablative high-dose chemo-or chemo-radiotherapy and bone marrow transplantation are highly susceptible to systemic fungal infections during neutropenia, immunosuppression or graft-versus-host disease (GVHD). The most frequently isolated fungal pathogens from neutropenic patients are Candida and Aspergillus species, and infections with these pathogens are often fatal. 5 Thus, even in culture-negative cases, systemic antimycotic therapy should be added early to antibiotic therapy.
In autograft patients, the incidence of infections commonly decreases after haematological recovery with a few exceptions. 6 After allogeneic marrow or blood stem cell transplantation, the immune system remains compromised for at least 1 year. A severe immune defect results with acute or chronic GVHD, and these patients have an increased susceptibility to fungal and viral infections. 7 Infection-related issues on transplant units are first, a possible change of microbial pathogen spectrum over the years with specific prophylactic and therapeutic drug regimens, and second, infection surveillance of transplantation procedures with the aim of quality control. Here, we report the infections in 409 consecutive patients from 1990 to 1997 as a single centre experience.
Patients and methods

Diagnoses, conditioning therapy, transplantation and GVHD prophylaxis
Over a 7 year period from February 1990 to April 1997, 409 patients were admitted to our BMT unit for primary or secondary transplantation or for treatment of transplantrelated complications. Three hundred and seventy-five patients were transplanted for the first time, 12 patients were retransplanted due to a relapse of malignancy or for treatment protocol reasons and three patients received a stem cell boost after primary transplantation. Nineteen patients were readmitted for treatment of infection (n = 10), cytopenia (n = 6), stem cell mobilisation with cyclophosphamide (n = 1), relapse (n = 1), and severe GVHD (n = 1).
Two hundred and twenty-six patients (55.3%) were male, and 183 (44.7%) were female. The median age was 32 years, with a range from 6 months to 65 years. The underlying diseases in the 409 treatment episodes were mainly acute and chronic leukaemias in 140 and 68 cases, respectively. Forty-seven patients suffered from solid tumours. Two hundred and forty-five patients were allografted, 177 autografted, and six patients had a syngeneic twin donor ( Table 1) .
Prophylaxis of GVHD in the allogeneic setting was with cyclosporin A, low-dose methotrexate and human immunoglobulin. One hundred and two patients were treated with anti-thymocyte globulin (ATG). Anaerobic gut decontamination with metronidazole was given in 109 cases. Table 1 shows the high-dose therapy regimen used for conditioning.
All patients were nursed in laminar air flow rooms; 133 patients (33%) were additionally treated in protected environments (PEC). Haemopoiesis was stimulated with G-CSF given as a continuous infusion from day +1 after graft infusion until stable leukocyte engraftment.
Antimicrobial prophylaxis
Anti-infectious prophylaxis (Table 2) was initiated immediately after admittance to the BMT unit. Three hundred and sixty-two patients received quinolone antibiotics for antibacterial prophylaxis, 33 predominantly paediatric patients received miscellaneous drugs due to suspected side-effects of quinolones in children. Antimycotic prophylaxis was mainly with fluconazole (n = 370) or itraconazole (n = 8) given systemically. One hundred and eighty two patients received additional non-absorbable oral antimycotics, either amphotericin B (n = 147) or nystatin (n = 35). In 25 episodes, antimycotic prophylaxis was carried out with non-absorbable drugs alone. Two patients with a history of systemic mycotic infection were treated with amphotericin B intravenously as antifungal prophylaxis. Anti-Pneumocystis prophylaxis was with trimethoprim-sulfamethoxazole 3 days weekly in 356 episodes, with nebulised pentamidine monthly in 31 episodes, and consecutively with both drugs in 15 cases. Antiviral prophylaxis was started on day +1 after transplantation with aciclovir (n = 386), ganciclovir (n = 5), or both drugs given consecutively (n = 10). Antibacterial prophylaxis was stopped after the onset of antibiotic therapy and antimycotic prophylaxis after the onset of systemic antifungal therapy for suspected or documented infection.
Diagnosis of infection
Diagnosis of fever of unknown origin was made after the occurrence of a body temperature of у38.2°C. Resolution of fever was defined as the first of 3 days with a maximum temperature of 37.5°C. Site-specific infections were diag- 
Antimicrobial therapy
Broad-spectrum antibiotic therapy was started immediately the temperature rose above 38.2°C or higher, or for documented or suspected bacterial infection. Blood cultures were drawn prior to antibiotic therapy and then daily until the fever resolved. X-ray examination of the chest was carried out. Serologic tests for Aspergillus or Candida antigen were performed at least weekly. Urine culture, oral, rectal and nose swabs were taken prior to antibiotics and then at 591 Table 2 Anti-infectious prophylaxis least once weekly. Special diagnostic procedures such as computed tomography X-ray, bronchoalveolar lavage or obtaining tissue biopsies were carried out when necessary. A combination of ceftazidime and vancomycin was given as first-line antibacterial therapy. In the event of sideeffects, vancomycin was replaced by teicoplanin and ceftazidime by piperacillin or imipenem-cilastatin. In the event of no response of fever or infection to therapy within 24-48 h, an aminoglycoside was added.
When fever did not respond to antibiotics within 72 h, or when patients developed a second episode of fever after successful antibiotic therapy, or for documented or suspected mycosis, systemic antifungal treatment consisting of intravenous infusion of conventional or liposomal amphotericin B was initiated. Clinical signs suggestive of mycosis included fever or pulmonary infiltrates that did not respond to antibiotics.
Further modifications of antimicrobial therapy such as addition of erythromycin for treatment of suspected atypical pneumonia or clindamycin for treatment of soft tissue infections were made according to results of surveillance cultures and serological tests, and from the clinical features and course of infection.
Antiviral therapy with ganciclovir and anti-CMV hyperimmunoglobulin was initiated after diagnosis of viral infection by culture or molecular genetic methods, or in the case of clinical evidence of viral infection.
Data collection and analysis
Data were collected with database software Access (Microsoft, Munich, Germany) and analysed using the computer software Excel (Microsoft, Munich) and WinSTAT (Kalmia Co., Cambridge, MA, USA). The independent t-test or the Mann-Whitney U test was used for the comparison of two groups, and datasets with more than two subgroups were compared by variate analysis.
Results
Engraftment
An engraftment analysis was performed for all patients grafted, regrafted, and boosted (n = 390). Nineteen patients admitted for other reasons were excluded. The mean duration to engraftment with 1000 granulocytes/l was 17.6 days (median 16, range 0-103), and to 1500 leukocytes/l 19.1 days (median 17, range 0-110) after transplantation. In cases of death or discharge of patients with aplasia or cytopenia, these points were defined for statistical reasons as the endpoints of cytopenia and aplasia.
The mean time to engraftment with 1000 granulocytes/l and 1500 granulocytes was shortened by use of G-CSF (n = 327/390), with mean values of 17.2 Ϯ 11.9 vs 19.8 Ϯ 8.5 days (P = 0.45, NS) and 18.5 Ϯ 12.1 vs 22.4 Ϯ 8.6 days (P = 0.015). Shorting of engraftment time by G-CSF was highly significant in the autologous setting (13.2 Ϯ11.8 vs 24.1 Ϯ 9.9 days, P Ͻ 0.001, and 13.9 Ϯ 9.3 vs 27.1 Ϯ 9.9 days, P Ͻ 0.0001), but not after allogeneic transplantation (18.2 Ϯ 7.4 vs 20.3 Ϯ 11.1 days, 22 Ϯ 12.9 vs 20.7 Ϯ 7.5 days, both NS). Engraftment was fastest in blood cell transplantation and slowest in autologous and matched unrelated donor bone marrow transplantation, as expected. The time to 1000 granulocytes was slightly delayed by CMV seropositivity (191/390 patients) (CMV− 16.8 Ϯ 11.9 vs CMV+ 18.5 Ϯ 11.0 days). Delay of engraftment to 1500 granulocytes was significant (CMV− 17.9 Ϯ 10.5 days vs CMV+ 20.4 Ϯ 12.8 days, P = 0.03). Forty-three patients were transferred to peripheral wards with cytopenia (n = 22), or died without engrafting after allogeneic (n = 18) or autologous transplantation (n = 3) for the reasons given below (see the section on Overall outcome).
Fever and infections
Three hundred and nineteen of 409 (78%) of all patients developed at least one episode of fever with temperatures of 38.2°C or above. Subfebrile temperatures occurred in 31 (7.6%) patients, and only 14.4% (59/409) patients remained free of fever. Fifty-three patients (13%) developed a second episode. A second episode of fever was more frequent in patients undergoing allogeneic (18.4%) than autologous (4.9%) transplantation (P Ͻ 0.001). The median duration of fever was 5 days, with a range of 0-85 days. Allo-patients had a significantly longer overall duration of fever than auto-patients (8.9 Ϯ 9.9 vs 5.9 Ϯ 7.3 days, P Ͻ 0.001). Overall duration of fever was significantly influenced by CMV seropositivity prior to transplantation (207/409 patients) (CMV+ 8.7 Ϯ 10.1 vs CMV− 6.7 Ϯ 7.8 days, P Ͻ 0.03).
The influence of protected environment (PEC) on incidence and duration of fever was analysed only for the allogeneic setting. The incidence of a second episode of fever was significantly higher in the group nursed under standard conditions (34/137) vs protected environment conditions (11/108) (P Ͻ 0.004). There was only a trend (P = 0.06) to a shortened overall duration of fever by PEC (7.6 Ϯ 8.2 vs 10 Ϯ 11 days). However, in this context it must be pointed out that very few MUD transplants were performed up to 1994, when PEC nursing was stopped.
Types and sites of infections are shown in detail in Figure 1 . The most frequent diagnosis was fever of unknown origin (n = 207, 50.6%) without differences between allo-and autografted patients. Fifty-one (12.5%) of the patients had septicaemia followed by pneumonia (n = 45, 11.0%). Infections of central venous lines (alone or in combination) were more frequent in autograft (8.5%) than in allograft (4.5%) patients, a possible effect of the preferred use of surgically inserted Quinton catheters for allogeneic transplantation. Site-specific infections other than infected central venous catheters were more frequent in allograft patients (n = 45, 18.4%) than in autograft patients (n = 12, 7.3%). The probability of acquiring a sitespecific infection was higher after allogeneic transplantation, in patients with veno-occlusive disease of the liver (P Ͻ 0.05), or in older patients (30.4 Ϯ 15.2 vs 34.2 Ϯ 15.3 years, P Ͻ 0.021). No association was found with CMV status, PEC nursing, or G-CSF administration. Sixty-eight patients, including several patients with subfebrile temperatures, had no evidence of infection. The probability of undergoing grafting without any infection was higher for autograft than allograft patients (23.2 vs 12.3%). These 68 patients were disregarded in the futher analysis of infections.
Microbial pathogens
Pathogens were isolated from 84/341 (24.6%) of all patients with a slightly higher rate in allograft (58/215, 27.0%) than in autograft patients (26/126, 21.4%). Gram-positive cocci were the most frequent bacteria isolated. 73.8% of all patients with documented infections were infected with gram-positive cocci, with minor differences between allogeneic (72.4%) and autologous (76.9%) transplantation. Infections with Enterobacteriaceae were infrequent and occurred only in allo-transplants. Pseudomonas spp. and other nonfermentative gram-negative rods were responsible for 14.3% of culture proven infections. Aspergillus spp. and Candida spp. were responsible for 13.1% each -together for 26.2% -of documented infections. While culture proven mycoses reflected 36.2% of documented infections in allogeneic patients, only one 1/26 (3.8%) of the infections in autograft patients was caused by fungi (Aspergillus and Candida). Table 3 and Figure 2 show details. 62% of the microbes were isolated from blood culture, 14% from CVL tips and 12% each from bronchoalveolar lavage or sputum, and from surveillance cultures.
CMV infections were only included in this and the further analysis after growth of viruses in conventional cell 593 Table 3 Microbial pathogens isolated from patients with infections culture. Methods of diagnosing CMV disease have improved dramatically during this time. Thus, we decided to exclude any bias in methodological developments. Altogether, 69 allograft and nine autograft patients were treated for suspected or documented infections with cytomegalovirus.
Response of infections
Response of infection was defined as a resolving fever, resolving or improvement of clinical signs, and clearance of positive cultures, when appropriate. The cumulative response rate to antimicrobial chemotherapy was 66.9%, with a slight advantage in the allogeneic setting (69.8 vs 61.9%) (Figure 3 ). The response rate to first line antibiotics was 27.9%, with no differences between allo-and autograft patients. Supplementing the antibiotic therapy with aminoglycosides improved the response rate by an additional 13.5%. Overall response to systemic antimycosis was 14.1%, with minor differences between the allogeneic and autologous setting. 19.7% of patients responded at engraftment, with differences between allograft (14.4%) and autograft (28.6%) patients. The failure rate was higher for allograft (12.6%) than for autograft patients (4.8%).
Changes from 1990 to 1997
To investigate a possible pathogen shift from 1990 to 1997, the 409 episodes were divided into three cohorts treated from 1990 to 1992 (n = 131), from 1993 to 1994 (n = 119), and from 1995 to 1997 (n = 159). The prevalence of grampositive bacteria increased from 50% to 55.2%, and finally to 64.5% in the latest treatment group. Enterobacteriaceae did not occur from 1990 to 1992. The percentage of nonfermenting gram-negative rods seems to have decreased. About 20% (18.8-24.1%) of isolated microbes are fungi, with no evidence of any trend (Figure 4 ).
Overall outcome
Three hundred and sixty-nine patients were discharged from the BMT unit or transferred to peripheral wards alive. The mean follow-up was 30.2 days. Forty (9.8%) patients died, with significant differences between allograft (37/241, 15.1%) and autograft (3/164, 1.8%) patients, P Ͻ 10 −5 . Three autograft patients died in the early post-transplantation phase; one died from bilateral Aspergillus flavus pneumonia, and the other patients from severe organ toxicity from high-dose therapy and VOD. Thirty-seven patients died after allogeneic transplantation. Their mean age (33.4 Ϯ 11.3 years) was significantly higher (P Ͻ 0.05) than the age of patients surviving allotransplantation (28.6 Ϯ 14.3). Causes of death were infections with (n = 20) or without severe organ toxicity (n = 4) as specified below, GVHD (n = 6), toxicity (n = 5), and bleeding complications (n = 2).
Details of patients (n = 25) who died from, or who died due to secondary infection are given in Table 4 . The risk of dying from infection was higher for allograft patients (n = 24/215, 11.2%) than for autograft patients (1/126, 0.8%). It must be pointed out that 15/25 patients (60%) with fatal infections had deep or systemic mycosis caused by Aspergillus spp. (n = 11) or Candida spp. (n = 4). Three of the remaining patients had severe infection with Pseudomonas aeruginosa. Altogether, infections were responsible 595 Table 4 Deaths from, or secondarily due to, infections
Cause of death n Pathogens Source of systemic infection/complications
Pneumonia 10 Aspergillus spp. (n = 7) Aspergillus-sinusitis 1 (autologous)
Ps. aeruginosa (n = 1) Aspergillus-septicaemia S. marcescens (n = 1) Pseudomonas-septicaemia Unknown (n = 2) CNS infection 4 Aspergillus spp. (n = 3) Aspergillus-septicaemia (n = 2) Unknown (n = 1) Septicaemia 6 Candida krusei (n = 2) Ps. aeruginosa (n = 2) Unknown (n = 2) Multi-organ failure 4 Candida spp.
Aspergillus-mastoiditis Secondary to infection
Aspergillus spp. (pneumonia = 2 septicaemia = 1
Candida krusei FUO = 1) Unknown or associated with 62.5% of deaths in the early phase after transplantation.
Discussion
Several studies report infectious complications in cohorts of consecutive marrow or stem cell graft recipients, but only a few deal with more than 200 patients. 8, 9 Two publications report data concerning aspergillosis and other fungal infections in 549 and more than 1500 patients, respectively. 10, 11 We have investigated the infections in 409 consecutive treatment episodes of patients hospitalised on a single BMT unit during 7 years in a retrospective analysis. Over the 7 year period, no major changes in antimicrobial prophylaxis occurred. Standard antimicrobial prophylaxis was identical for auto-and allograft recipients. In accordance with Russell et al, 12 we did not find any advantages for patients nursed under PEC.
Overall incidence of infections and febrile episodes was high, with 83.4%, 12.3% of all allograft patients, and 23.2% of autograft patients remaining free of infection. There were no differences with respect to experiencing an episode of fever of unknown origin during aplasia: the rates were 50.2% (allo) and 51.2% (auto), respectively. These rates are quite similar to those reported by Kolbe et al 1 for autograft patients.
Duration of fever and time to engraftment were prolonged by allogeneic transplantation and by positive CMV serology prior to transplantation. Emergence of a risk for BMT patients of acquiring other infections by cytomegalovirus is known. 8, 13 Stimulation of haemopoiesis by G-CSF after transplantation was more effective in autograft than in allograft patients. These observations can be easily explained by immunological mechanisms. Haemopoietic recovery is known to be an important factor for defeverescence and resolution of infections in neutropenic patients. Latent or active infection with human cytomegalovirus can inhibit myelopoiesis in vitro as well as in vivo. 14, 15 Acute or chronic GVHD is frequently associated with prolonged leukopenia and thrombopenia and predisposes to infections. 16, 17 Site-specific infections occurred more frequently in allograft than in autograft patients. Reasonable explanations are first, the prolonged neutropenia after allogeneic transplantation, second immunologic differences between graft and host and third, differences in underlying diseases and pretreatment histories of allo-and autograft patients. A history of prolonged neutropenic episodes with preceding courses of cytoreductive therapy is a known risk factor for the acquisition of infections during transplantation. 18 Fever during neutropenia demands immediate therapy, complicating the isolation of pathogens responsible for the infection. These factors might allow breakthrough of infections from fever of unknown origin with or without isolation of pathogens. This is supported first, by our observation of significantly longer febrile episodes and of significantly more fever episodes in allograft patients and second, by the autopsy study published by Nosari et al, 19 who described a higher frequency of pathogens isolated at autopsy than had been diagnosed clinically. The only exception -the higher incidence of central venous line infections in autograft patients -is easily explained by the policy of our centre of performing allotransplantation with Quinton catheters surgically inserted in an operation theatre, and not with central venous lines.
The spectrum of isolated microbial pathogens was likewise different between autograft and allograft patients. 24.3% of pathogens isolated from allograft patients were fungi. In contrast, only 10.4% of the microbes isolated from autograft patients were fungi. The high incidence of mycoses after allotransplantation is well described in the literature. The reasons are the same as mentioned above. 16.8% of the pathogens were gram-negative rods with minor differences between transplant types. Enterobacteriaceae were not isolated from autograft patients and were isolated in only six cases from allograft patients. Fifty-eight percent of the bacteria were gram-positive cocci. A pathogen-shift from gram-negative to gram-positive bacteria has been recognised since the introduction during the 1980s of newer antibiotic drugs highly active in the treatment of Enterobacteriaceae and since the introduction of quinolones as prophylaxis. 6 Furthermore, our data confirm the effectiveness of systemic quinolone prophylaxis in the prevention of gram-negative infections. 20 The predominance of gram-positive bacteria showed a further increase from 50% (1990-1992) to 64% (1995-1997) . However, in contrast to other investigators, we observed no lethal gram-positive infections. 21 This observation lead us to conclude that neither the systemic quinolone prophylaxis nor the first-line antibiotics consisting of ceftazidime/vancomycin lost any potency due to upcoming resistance of bacteria over the 7 year period, and that there is no need for a change in policy. The incidence of Aspergillosis showed a slight increase, which could be a result of the increasing number of MUD transplants. However, due to the small absolute number of Aspergillus infections, we did not subspecify the data. The overall percentage of systemic mycoses remained quite constant over the years.
Attempts to isolate microbial pathogens were most successful from blood and from central venous lines. However, it should be pointed out that, in contrast to the low frequency of performing broncho-alveolar lavage, this procedure led to isolation of 12% of all pathogens detected. Examinations of stool, urine and surveillance swabs were less successful, but taken together, 12% of the microbes were isolated from these specimens. These data lead us to recommend surveillance cultures.
The average response rate of infections to antimicrobial therapy was 66.9%. The higher rate in the allogeneic vs autograft setting (69.8 vs 61.9%) is easily explained by the faster engraftment in autografted patients (28.6 vs 14.4%) and emphasizes the importance of a rapid haemopoietic recovery. The response rate to antibacterial therapy was 51.7%, with only a small difference between allo-and autograft patients. An average of 14.1% of all infections responded to antimycotic treatment, with an advantage of 15.8% compared to 11.1% for allograft patients. These results for bone marrow transplantation are in accordance with reports of patients with haematological malignancies undergoing standard chemotherapy. Response of allograft patients to antimycotics should encourage earlier use of systemic antimycotics in the antimicrobial escalation therapy for treatment of fever of unknown origin, especially in this subset of patients. This policy could help shorten fever periods, avoid escalation of antibacterial therapy, and perhaps stop breakthrough of fungal infections, and improve the outcome of patients. Side-effects of systemic antimycotic therapy with the standard drug amphothericin B can be avoided by using newer formulations of this drug with a very low frequency of adverse effects. 22, 23 Despite the high response rate of infections to antimicrobial therapy, infections remain a predominant cause of death in patients undergoing haemopoietic stem cell transplantation. 62.5% of the deaths were caused by, or secondarily due to, infections. In contrast to one of three infectionrelated deaths in the autograft group, infections were responsible for 24 of 37 (64.9%) deaths in the allograft group. Aspergillus spp. and Candida spp. were involved in 60% of all fatal infections. In general, 15 of 22 (68.2%) of culture proven mycoses were deadly. The mortality of Pseudomonas spp. infections was 30% and only one of six (17%) infections with Enterobacteriacaeae was fatal. No patient died of infection from gram-positive bacteria. Our data clearly show that early mortality after autologous haemopoietic stem cell transplantation is very low (3/126, 2.4%), and support other investigators who have observed that early mortality is significantly higher after allografting and for elder patients. 8 Culture proven systemic mycosis after allogeneic transplantation results in a high probability of death. This emphasizes the necessity for developing an effective antifungal prophylaxis regimen. Candida krusei or glabrata may proliferate with fluconazole-prophylaxis. 24, 25 Furthermore, fluconazole has no effect against Aspergillus spp., and the efficacy of itraconazole in the prevention of systemic aspergillosis requires confirmation in further trials. It has been known for several years that nursing patients in rooms with HEPA-air reduces the incidence of pulmonary aspergillosis during neutropenia. 20 Some investigators have used low-dose intravenous amphotericin B for systemic antimycotic prophylaxis with success. 26 The optimal antifungal prophylaxis for patients undergoing bone marrow transplantation must be defined by randomised studies.
Prophylaxis of gram-negative infections with quinolone antibiotics is still effective, but less so in preventing grampositive infections mainly caused by Streptococcus spp. and Enterococcus spp. Some investigators have added antibiotics with activity against gram-positive bacteria, such as vancomycin or penicillin, to their prophylactic regimen and reported a reduction of gram-positive infections. 27 Our data show that gram-positive infections are relatively frequent but, in contrast to other investigators, we observed no fatalities. Vancomycin has been shown to be a drug with high activity against gram-positive infections, but it may cause nephrotoxicity. Our results with gram-positive infections in haemopoietic stem cell transplantation, and its profile of adverse effects do not lead us to recommend it for prophylactic use.
We conclude, first, that an adequate regimen for the prophylaxis and treatment of bacterial infections in haemopoietic stem cell recipients is currently available, second, infections still remain a major cause of death in patients undergoing haemopoietic stem cell transplantation, especially in the allogeneic setting, third, systemic fungal infections lead to a high probability of death for allograft recipients, and fourth, anti-infection research in transplantation should focus on strategies for better antifungal prophylaxis and therapy.
